NY‐ESO‐1 antigen‐reactive T cell receptors exhibit diverse therapeutic capability-Reference-Cited by-同舟云学术

NY‐ESO‐1 antigen‐reactive T cell receptors exhibit diverse therapeutic capability

Published:2012-09-14 Issue:6 Volume:132 Page:1360-1367
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Sommermeyer Daniel¹,Conrad Heinke²³,Krönig Holger³,Gelfort Haike¹,Bernhard Helga²³⁴,Uckert Wolfgang¹⁵

Affiliation:

1. Max‐Delbrück‐Center for Molecular Medicine, Berlin, Germany

2. Division of Immunogenetics, German Cancer Research Center (DKFZ), Heidelberg, Germany

3. Department of Hematology/Oncology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany

4. Department of Hematology/Oncology, Klinikum Darmstadt GmbH, Darmstadt, Germany

5. Institute of Biology, Humboldt University Berlin, Berlin, Germany

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.27792

Reference28 articles.

1. NY‐ESO‐1: Review of an Immunogenic Tumor Antigen

2. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

3. Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

4. Identification of NY‐ESO‐1 epitopes presented by human histocompatibility antigen (HLA)‐DRB4*0101–0103 and recognized by CD4(+) T lymphocytes of patients with NY‐ESO‐1‐expressing melanoma;Jager E;J Exp Med,2000

5. LUD 00‐009: phase 1 study of intensive course immunization with NY‐ESO‐1 peptides in HLA‐A2 positive patients with NY‐ESO‐1‐expressing cancer;Bender A;Cancer Immun,2007

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Allogeneic Tumor Antigen-Specific T Cells for Broadly Applicable Adoptive Cell Therapy of Cancer;Cancer Immunotherapies;2022

2. Generation of Epstein-Barr Virus Antigen-Specific T Cell Receptors Recognizing Immunodominant Epitopes of LMP1, LMP2A, and EBNA3C for Immunotherapy;Human Gene Therapy;2021-09-01

3. Mutated RAS: Targeting the “Untargetable” with T Cells;Clinical Cancer Research;2019-09-11

4. NY-ESO-1: a promising cancer testis antigen for sarcoma immunotherapy and diagnosis;Chinese Clinical Oncology;2018-08

5. PLAC1-specific TCR-engineered T cells mediate antigen-specific antitumor effects in breast cancer;Oncology Letters;2018-02-16